P2.09-16 Heterogeneity Analyses of MSLCs-Especially in the EGFR Mutation-Positive Ones Y. Xu, X. Wang, Y. Cai, Y. Guo, C. Sun, K. Ma Cancer Center, The First Hospital of Jilin University, Changchun/CN Background: Multiple synchronous lung cancers (MSLCs) are diagnosed as multiple tumor nodules in the same or different lung lobes. MSLCs present a clinical dilemma whether they are primary tumors or metastases. Recent studies showed that MSLCs shared an identical germline genetic background and environmental exposure in the same individual patient, however, different tumor nodules showed highly different heterogeneity, even in all the EGFR mutation-positive focuses. Therefore, we performed this study to further analyze MSLCs as to estimate the pathology and molecule heterogeneity among these nodules. Method: Tumor samples were obtained from nine patients diagnosed with MSLCs. Immunohistochemistry were performed by professional pathologists. Whole-exome sequencing (WES) was conducted by IlluminaNovaseq with sequencing depth of 200X. NeoTyping was used to describe the dispersion of sequencing data among MSLCs of the same patient. Result: We found different tumor nodules showed obviously pathological and molecular heterogeneities in the same individual ( Figure 1 ). More different dispersion was observed among the nodules with more different pathologies in the same patient. The dispersion of 20%, 50% and 100% were observed in MSLCs with the same driver genes (such as EGFR exon21 L858R and L861Q) of lung adenocarcinoma, different evolutional stages (AAH, MIA and IA) and completely different pathologies (adenocarcinoma and squamous cancer), respectively. All the sequencing data showed MSLCs had different gene information, even in all the EGFR mutation-positive nodules, maybe similar, but not the same, which supported that each nodule in one patient was independent with others. Conclusion: MSLCs could be independent with each other due to their pathological and molecular heterogeneities, even for EGFR mutation-positive nodules which hold the same driver gene, but different mutation site in just one patient. WES should be an effective way to recognize this heterogeneous characteristic, which would be helpful for the whole precise management of one MSLC patient. Background: Posthumous rapid tissue donation (RTD) provides an opportunity to understand treatment-resistant lung cancers with preservation of valuable tumor and non-tumor specimens from primary and metastatic sites. Method: Consent to participate in the lung RTD program was obtained during patient care. When death occurred, tumor and paired non-tumor, cytology, and blood specimens were preserved as formalin-fixed and frozen specimens. Tissue sections were evaluated with hematoxylin and eosin (HandE) staining and programmed death ligand-1 (PD-L1) immunohistochemistry. Massively parallel sequencing was performed on 11 specimens. Result: To date, 21 patients consented to participate in the RTD program. Post-mortem specimens (N¼180) were preserved from 9 patients and the other patients remain alive. Evaluation of HandE slides confirmed well-preserved tissue. PD-L1 immunohistochemistry revealed heterogeneous expression between tumor sites. Next generation sequencing provided high quality data on all 11 tested samples. Conclusion: Rapid donation of post-mortem tissue from lung cancer patients is feasible and provides high quality specimens for research. Post-mortem tissue collection of primary and metastatic tumors facilitates studies of tumor mutation evolution, mechanisms of drug resistance, and biomarker expression. Keywords: rapid autopsy, post-mortem, tissue donation Background: Sclerosing pneumocytoma is a rare benign pulmonary neoplasm, which in Asia, most commonly occurs in middle-aged women. Because of the rarity of this disease, no data is available on its nationwide incidence or clinical characteristics. This nationwide survey was conducted by the Korean Cardiopulmonary Pathology Study Group to document the incidence and clinical characteristics of sclerosing pneumocytoma in a Korean population. Method: A total of 220 cases of sclerosing pneumocytoma diagnosed at 15 tertiary medical centers in Korea during the period 1994 to 2012 were collected and retrospectively studied. Clinical parameters evaluated were sex, age at diagnosis, tumor size, tumor location, surgical procedure type, status of lymph node metastasis, and distant metastasis. Result: The female to male ratio was 7.15:1, and the tumor occurrence rate in middle or lower lobes was significantly higher than that in upper lobes (P < 0.001). The peak incidence rate appeared to occur in the sixth decade of life. Tumor was located in right lung in 121 cases and in left lung in 96 cases (43.6%). The mean tumor size in female patients (2.63 cm) was significantly larger than in male patients (2.19 cm) (P ¼ 0.037). In 2 cases (0.9%) metastatic tumors were found in regional lymph nodes, and one case (0.5%) showed metastatic lymph nodes and distant metastasis in a lumbar vertebra. Conclusion: Age distributions, mean tumor sizes, and tumor locations were similar to those previously reported for sclerosing pneumocytoma, and the female-to-male ratio in our Korean cohort was similar to those previously reported in Asia, but higher than those reported in the West. Background: Traditional pathological assessment of tissue sections involves subjective analysis of complex and heterogeneous features, typified by the challenge of 'measuring' PD-L1 expression in non-small cell lung cancer (NSCLC) as a guide to its treatment with immune checkpoint inhibitors. Such heterogeneity is generally perceived as a problem but might, in fact, reflect not only biologically important epitope variation, but also important features of the tumour microenvironment and, by extension, be a tool for predicting behaviour. In-depth analysis of a single slide of a tumour by digital pathology, image analysis and machine learning makes more accurate and meaningful analysis a possibility. Method: Expression of PD-L1 was assessed by immunochemistry in 250 sections from 137 resected NSCLCs using the Ventana SP263 antibody and a validated protocol and its distribution compared with morphology as revealed by corresponding HandEstained sections. Slides were scanned to create a digital image using Aperio Scanscope with division of images into 1mm 2 squares using QuPath opensource software, each of which was assigned x and y coordinates. Squares were assessed subjectively by two pathologists for morphological features and PD-L1 expression and also subject to automatic image analysis including cell counting and membrane detection. Co-ordinates and values were stored in Microsoft Excel and a digital database was generated for every slide. In-depth analysis of digital data points was achieved using "R" software custom algorithms that included simulating biopsy sampling and applying spatial analysis packages. Result: The resulting database, comprising approximately 30,000 data points from the 137 tumours, is being used to simulate needle-core biopsies, assess heterogeneity of PD-L1 expression and relate this to the tumour micro-environment including immune cell populations, immune signature and tumour mutational burden. Conclusion: The vast amount of information in every NSCLC cannot be extracted by conventional histopathological analysis. By utilising new technologies and considering alternative paradigms for data acquisition, powerful new approaches may be developed that give information pertaining to not just diagnostic and prognostic features of a tumour, but behavioural traits including likely responses and resistances to novel drugs such as immune checkpoint inhibitors. The methodology described here is an attempt to extract these data in a more objective way and complement the still crucial subjective analysis that is traditionally the prerogative of the histopathologist. Background: Lung adenocarcinoma with solid pattern (SP) predominant subtype was reported to be associated with poor prognosis. However, whether minor components of SP predict poor prognosis remains unknown. The present study aimed to clarify the influence of different proportion of SP on the prognosis of pathological stage I lung adenocarcinoma. Method: Tumors of 341 patients who underwent radical resections were classified according to the IASLC/ATS/ERS classification. Patient contained less than 5% SP in the tumor was determined SP negative and SP positive patients were reclassified to SP minor (5-50%) and SP major (50%) groups. Survival analyses were used to determine the association between each group with patient survival. Result: 50 (15%) patients were SP positive and compared to SP negative group they showed a significantly lower fiveyear disease-free survival (DFS) rate (85.2 vs. 55.4%, p<0.001) and overall survival (OS) rate (97.3 vs. 66.7%, p<0.001). Multivariate analysis for DFS showed that SP positive, lepidic pattern negative, KRAS mutation and pathological stage IB were independent poor prognostic factors. In addition, higher proportions (<5%, 5e50% and 50%) of SP components were associated with a poorer prognosis (85.2, 76.6, and 40.0% of 5y-DFS, respectively; p<0.001). Conclusion: Solid pattern is a significant poor prognostic factor and an indicator of early recurrence after radical resection for early stage lung adenocarcinoma. Patients with tumors harboring a higher ratio of SP components have worse survival. Keywords: lung adenocarcinoma, Prognosis, Solid pattern
